CP-547632 is a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor, and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM.

Potent VEGFR inhibitor; also aromatase inhibitor

MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase.

BIBF 1202 is the carboxylate metabolite of BIBF 1120, which is an oral triple angiokinase inhibitor targeting VEGFR, PDGFR, FGFR.

BMS-798433 shows greater than 50% TGI for at least one tumor doubling time with no toxicity observed during 14 days in GTL-16 human gastric tumor xenografts model.

2,4-Pyrimidinediamine with linker is a multikinase inhibitor with a -NH2 terminal linker.

Regorafenib is a multi-target inhibitor. It can inhibit the activities of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 and their IC50 values ​​range from 1.5 nM to 46 nM.

TMB, a chromogenic substrate, is used in staining procedures in immunohistochemistry as well as being a visualising reagent used in enzyme-linked immunosorbent assays (ELISA).

Regorafenib HCl can inhibit many kinases including RET (IC50 = 1.5 nM), Raf-1 (IC50 = 2.5 nM), VEGFR2 (IC50 = 4.2 nM), VEGFR1 (IC50 = 13 nM), PDGFRβ (IC50 = 22 nM) and VEGFR3 (IC50 = 46 nM).

WHI-P154 is a specific inhibitor of JAK3 with IC50 value of 1.8 μM, almost shows no activity against JAK1 or JAK2.

Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.

Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3. Chloropyramine hydrochloride may be useful in the treatment of invasive breast cancer.

SU 4312 is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively), which is selective over EGFR and c-Src tyrosine kinases.

Glumetinib is a novel, potent and highly selective inhibitor of c-Met.

5(6)-TAMRA contains a carboxylic acid that can be used to react with primary amines via carbodiimide activation of the carboxylic acid. It is a bright, orange-fluorescent dye that produces conjugates with absorption/emission maxima of ~555/580 nm.

Donafenib, also known as CM-4307, is a multikinase inhibitor of Raf kinase and receptor tyrosine kinases with IC50 of 6 nM, 20 nM and 22 nM for Raf-1, B-Raf and VEGFR-3, respectively.

Motesanib is an ATP-competitive inhibitor of VEGFR1 (IC50 = 2 nM), VEGFR2 (IC50 = 3 nM), VEGFR3 (IC50 = 6 nM) and Kit.

Vorolanib (CM082) is an orally active, potent VEGFR/PDGFR/DHODH inhibitor.